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Summary
Purpose:  To  determine  the  effectiveness  of  three  different  combinations  for  the  ‘‘loading
phase’’ in  the  treatment  of  diabetic  macular  edema  (DME),  using  bevacizumab  (BVZ),  triamci-
nolone (TCL)  and  subthreshold  macular  photocoagulation  (SMPC).
Methods:  Experimental,  longitudinal,  prospective,  comparative  and  blind.  Patients  were  ran-
domly assigned  to  three  treatment  branches:  Group  1:  BVZ  +  SMPC  (12  eyes),  Group  2:
SMPC +  BVZ  +  TCL  (7  eyes),  Group  3:  BVZ  +  TCL  (11  eyes).  Treatment  with  BVZ  and  TCL  was  given
every 4  weeks  for  3  months,  SMPC  was  applied  once  at  the  beginning  of  treatment.  Initial  and
ﬁnal measurements  of  best  corrected  visual  acuity  (BCVA),  central  macular  thickness  (CMT)  and
intraocular pressure  (IOP)  were  tested.
Results:  The  improvement  in  BCVA  and  the  reduction  in  CMT  was  statistically  superior  in  group
of BVZ  +  SMPCwhen  compared  to  the  other  groups.  There  were  no  differences  in  IOP.
Conclusions:  Combined  therapies  in  the  ‘‘loading  phase’’are  a  good  option  when  treating  DME.
Although the  group  with  BVZ  +  SMPC  obtained  the  best  results,  further  studies  with  longer  follow-
up and  a  higher  number  of  participants  to  establish  this  combined  therapy  as  the  ﬁrst  treatment
option are  required.
©  2015  Universidad  Autónoma  de  Nuevo  León.  Published  by  Masson  Doyma
México S.A.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
rg/li
c
p
o
e
a
((http://creativecommons.o
Introduction
Diabetic  macular  edema  (DME)  is  the  main  cause  of
visual  loss  in  patients  with  diabetic  retinopathy  (DR).  It  is∗ Corresponding author at: Servicio de Oftalmología. Hospital Uni-
versitario ‘‘Dr. José Eleuterio González’’ de la UANL, Av. Madero y
Gonzalitos S/N. Mitras Centro. Monterrey Nuevo León, Mexico.
E-mail address: drjesusgzz@gmail.com (J.H. González-Cortés).
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onsidered  to  be  the  number  one  cause  of  blindness  at  a
roductive  age  in  developed  countries.1--6 DME  is  the  result
f  alterations  of  the  inner  and  outer  blood-retinal  barri-
rs  (BRB)  due  to  the  imbalance  between  the  inﬂammatory
nd  angiogenic  factors  of  the  retinal  pigment  epithelium
PE)  and  the  vitreoretinal  interface.  Among  these,  there  is
he  vascular  endothelial  growth  factor  (VEGF),  the  hepato-
yte  growth  factor  and  the  interleukin  1B.  The  reduction
n  the  pigment  epithelium-derived  anti-angiogenic  factor,
 potent  anti-inﬂammatory,  antioxidant  and  anti-angiogenic
asson Doyma México S.A. This is an open access article under the
.0/).
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hich  regulates,  among  other  things,  VEGF  levels,  also  plays
n  important  role  in  DME  pathophysiology.7--9 The  treatment
ocuses  on  reestablishing  BRB,  modulating  inﬂammatory  and
ngiogenic  factors.  Among  the  current  options  to  accomplish
aid  effect,  there  are  the  thermal  laser  and  intravitreal  drug
herapies  (corticosteroids  and  anti-angiogenics).
The  laser  stimulates  the  PE,  acting  as  a  substance  modu-
ator  for  PEDF  and  VEGF.  Moreover,  the  thermal  destruction
f  the  outer  layers  of  the  retina  reduces  the  metabolic
emand  and  oxygen  expenditure  with  the  consequent  VEGF
eduction.10--18 Triamcinolone  is  the  main  intraocular  corti-
osteroid  in  the  treatment  of  RD,  DME  and  other  neovascular
nd  inﬂammatory  diseases  because  it  inhibits  overregulation
f  inﬂammatory  molecules  and  VEGF.  Part  of  this  regulation
as  completed  through  the  reduction  of  vascular  permeabil-
ty  in  the  retina  by  reducing  the  liberation  of  arachidonic
cid  derivatives,  such  as  prostaglandins.19--22 Bevacizumab
s  a  recombinant  humanized  monoclonal  antibody  (lgG1)
hich  uniﬁes  all  isoforms  of  VEGF-A.  It  was  approved  by  the
DA  in  2004  for  metastatic  colon  cancer  treatment.  Since
hen,  it  has  been  successfully  used  in  an  unofﬁcial  man-
er  to  treat  different  ocular  neovascular  illnesses,  such  as
ge-associated  macular  degeneration,  proliferative  DR,  neo-
ascular  glaucoma,  premature  retinopathy,  macular  edema
econdary  to  retinal  venous  obstruction  and  DME,  among
thers.  Even  though,  to  this  day,  it  has  not  been  approved
y  the  FDA  nor  the  COFEPRIS  for  its  ophthalmologic  use,
he  injection  of  1.25--2.5  mg  in  the  vitreous  cavity  has  been
erformed  in  a  safe  and  effective  manner.23--29 Different
egimes  in  DME  treatment  have  been  described.  The  laser
s  recommended  for  its  application  in  a  selective  manner
nd  on  a  single  occasion,  and,  if  necessary,  reapply  it  in
ntervals  of  no  less  than  12  weeks  apart.18,30,31 Intravitreal
harmacological  therapy  has  been  proposed  for  the  differ-
nt  ocular  neovascular  pathologies,  from  having  one  dose
nd  repeating  treatment  as  deemed  appropriate  by  the
xaminer  pro  re  nata  (PRN),  up  to  a  monthly  dose  for  24
onths,  without  regard  to  visual  and  anatomic  changes.32--41
his  study  showed  that  the  maximum  visual  and  anatomical
ffect  occurs  during  the  ﬁrst  three  doses,  and  those  fol-
owing  them  only  helped  to  maintain  the  inactivity  of  the
athology;  thus,  the  decision  in  the  selection  of  the  scheme
uring  this  ‘‘loading  stage’’  is  fundamental.  The  ‘‘treat
nd  observe’’  regime  is  currently  being  proposed.  This  is
o  apply  three  doses  in  a  row  with  an  interval  of  4  weeks
n  between  these  ‘‘loading  doses’’  until  accomplishing  the
aximum  visual  and  anatomic  effect,  repeating  the  same
reatment  PRN.42 Based  on  the  possible  synergy  between
he  laser,  the  corticosteroids  and  the  anti-angiogenics,
he  combination  between  these  has  been  utilized  with
 dual  intention;  to  accomplish  a  greater  visual  and
natomic  effect,  and  to  accomplish  the  minimum  number
f  repetitions  in  long-term  treatment  of  this  chronic  degen-
rative  illness.35,36,43--49 In  spite  of  all  of  this,  the  question
bout  which  combination  may  be  the  best  option  remains
nanswered.bjective
o  evaluate  effectiveness  with  three  different  treatment
ombinations  in  the  ‘‘loading  phase’’  of  diabetic  macular
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dema  (DME);  using  bevacizumab  (BVZ),  triamcinolone  (TCL)
nd  subthreshold  macular  photocoagulation  (SMPC).
ethod and materials
ontrolled  clinical,  experimental,  prospective,  longitudi-
al,  comparative  and  blind  essay,  including  those  patients
rom  the  Department  of  Ophthalmology  at  the  ‘‘Dr.  José
leuterio  González’’  University  Hospital  using  the  follow-
ng  inclusion  criteria:  male  and  female  with  diabetes  (type
 or  II),  18  years  of  age  or  older,  with  a clinical  and  tomo-
raphic  DME  diagnosis,  best  corrected  visual  acuity  (BCVA)
igher  than  20/400.  Patients  who  did  not  present  any  of  the
xclusion  criteria;  presence  of  signiﬁcant  cataract  (accord-
ng  to  the  researcher’s  criteria),  diagnosis  of  glaucoma,
itreous  hemorrhage,  previous  intraocular  surgery,  macular
aser  treatment  and/or  intravitreal  drug  therapy  in  the  three
onths  previous  to  the  study.  Patients  who  for  any  reason
id  not  complete  treatment  or  developed  complications  dur-
ng  treatment  were  eliminated.  The  protocol  was  evaluated
nd  approved  by  our  institution’s  Ethics  Committee  and  reg-
stered  under  the  code  OF11-010.  The  study  was  conducted
ollowing  the  guidelines  established  in  the  Helsinki  Decla-
ation  and  the  International  Conference  on  Harmonization
uidelines  for  Good  Clinical  Practices.  All  patients  signed
n  informed  consent  form  respecting  the  Ofﬁcial  Mexican
tandards  on  the  patients’  right  to  know  everything  about
heir  illness  and  its  possible  treatment  options.
Clinical  diagnosis  was  made  through  fundoscopy,  using
 magnifying  glass  of  90  diopters  and  a  Goldman  contact
ens  and  DME  was  considered  as  the  central  thickening  of
t  least  a diameter  of  1500  microns,  situating  the  center
f  this  circle  in  the  umbo  foveolar.  Tomographic  diagnosis
as  performed  whenever  there  was  a  central  macular  thick-
ess  (CMT)  greater  than  230  microns  using  the  ‘‘Macular
hickness  Map’’  scanning  modality  of  the  optical  coherence
omography  (OCT)  using  Stratus  OCTTM by  Carl  Zeiss.
Baseline  BCVA  measurements  were  taken  by  means  of  dis-
ant  subjective  refraction  with  a  Snellen  primer.  IOP  was
aken  by  means  of  an  applanation  tonometry  from  Goldmann
nd  clinical  and  OCT  ﬁndings  were  recorded.
Later,  the  randomized  selection  of  the  study  groups
as  made,  using  the  six-sided  die  technique:  numbers  1
r  4  to  group  1  (BVZ  +  SMPC),  numbers  2  or  5  to  group  2
BVZ  +  TCL  +  SMPC),  and  3  or  6  to  group  3  (BVZ  +  TCL).  In  this
tudy,  the  principal  investigator,  who  evaluated  the  study
t  the  beginning  and  ﬁnalized  the  treatment  regimen  dur-
ng  the  ‘‘loading  phase’’,  did  not  know  which  group  each
atient  belonged  to.
The  laser  was  only  applied  at  the  beginning  of  treatment
week  0),  with  the  aim  of  avoiding  possible  complications
rom  the  laser  threshold.  The  shots  were  made  on  sub-
hreshold  (invisible)  mode,50 using  VISULASTM 532s  laser
quipment  (Carl  Zeiss  Meditec  AG.  Jena,  Germany).
The  pharmacological  treatment  was  performed  on  week
,  repeating  at  weeks  4 and  8.  A  dose  of  1.25  mg  in  0.05  ml
f  BVZ,  commercial  name  AvastinTM (Genentech  Inc.,  South
an  Francisco,  CA,  USA/Roche  Mexico)  was  applied  each
ession.  The  TCL  utilized  was  ATLCTM (conservative-free),
istributed  by  GRIN  laboratories,  Mexico,  at  a rate  of  2  mg
n  0.05  ml  every  injection.  The  procedure  was  performed
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Table  1  Description  of  the  studied  population.
N  Minimum  Maximum  Average  Standard  deviation
Age  30  48.00  71.00  58.6000  6.51576
Initial VA  30  0.20  1.30  0.6933  0.39994
Initial IOP  30  10.00  19.00  14.1667  2.52003
Initial CMT  30  297.00  732.00  396.9333  121.17469
Final IOP  30  11.00  18.00  14.7333  2.25806
Final VA  30  0.10  1.30  0.6133  0.38572
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in  the  ‘‘cure  room,’’  with  prior  asepsis  and  antisepsis  of  the
eyelids  and  ocular  surface  with  a  solution  of  povidone-iodine
at  5%  (BetadineMR Alcon  Laboratories  Inc.,  Fort  Worth,  TX)
for  3  min  and  posterior  irrigation  with  a  balanced  saline  solu-
tion.  The  topical  anesthesia  applied  was  tetracaine  (PontiTM
Laboratorios  Sophia,  S.A.  de  C.V.,  Guadalajara,  Mexico).
The  injection  was  made  via  pars  plana  in  the  superotem-
poral  quadrant  (4  mm  from  the  corneal  limbo  in  phakic  eyes
and  3.5  mm  in  pseudo-phakic  eyes).  A  drop  of  moxiﬂoxacin
(VigamoxiTM,  Alcon  Laboratories  Inc.,  Fort  Worth,  TX)  was
applied  as  a  wide-spectrum  antibiotic  at  the  end  of  the  pro-
cedure,  which  was  used  prophylactically  at  a  rate  of  one
drop  every  6  h  for  three  consecutive  days.
The  IOP,  BCVA,  clinical  ﬁndings  and  CMT  were  docu-
mented  on  week  12  after  the  beginning  of  treatment,  and
these  results  were  compared  with  the  baseline  measure-
ments.  A  statistical  analysis  was  made  by  the  IBM  SPSS
Statistics  software,  with  a  descriptive  analysis  of  the  data,
which  was  compared  to  the  average  through  the  Student’s
t-test  for  related  samples.  p  <  .05  was  determined  to  be  a
statistically  signiﬁcant  difference.
Results
Our  study  included  30  eyes  from  30  patients,  with  ages
between  48  and  71  years  old,  an  initial  BCVA  of  .2  Log-
mar  (20/30)  to  1.3  Logmar  (20/400),  an  initial  CMT  average
of  396.93  m  and  an  initial  average  IOP  of  14.16  mmHg
(Table  1).  The  global  BCVA  change  was  from  .6933  to  .6133
Logmar  (p  =  .24),  a  statistically  insigniﬁcant  difference.
The  global  CMT  change  was  from  396.93  m  to  308.03  m
(p  =  .01),  a  statistically  signiﬁcant  difference.  There  were
no  signiﬁcant  differences  between  the  initial  and  ﬁnal
IOP,  which  was  from  14.16  mmHg  to  14.77  mmHg  (p  =  .176)
(Table  1).
In the  group  analysis,  we  found  that  the  average  change
in  BCVA  in  group  1  (12  eyes,  BVZ  +  SMPC)  was  from  .64  to  .46
Logmar  (p  =  .01),  a  statistically  signiﬁcant  difference  com-
pared  to  group  2  (7  eyes,  SPMC  +  BVZ  +  TCL)  which  was  from
.74  to  .67  (p  =  .28)  and  group  3  (11  eyes,  BVZ  +  TCL)  which
was  from  .71  to  .73  (p  =  .67).
In  the  same  way,  the  decrease  of  CMT  in  group  1  was  from
456.5  m  to  319.41  m  (p  =  .019),  a  statistically  signiﬁcant
value  in  comparison  to  group  2,  which  showed  a  decrease
of  385.28  m  to  290.57  m  (p  =  .110),  and  group  3,  which
showed  a  decrease  of  339.36  m  to  306.72  m  (p  =  .110).
There  were  no  signiﬁcant  differences  in  IOP  change  in  any  of
the  3  groups  (Table  2).  Two  patients  from  group  3  (BVZ  +  TCL)
a
s
t
t.00  308.0333  80.62107
nd  one  from  group  2  (SPMC  +  BVZ  +  TCL)  showed  cataract
rogression  which  required  surgery  more  than  IOL  place-
ent.
iscussion
ince  the  ﬁrst  results  of  ETDRS  were  published  in  1985,  mac-
lar  laser  became,  and  still  is,  the  ‘‘gold  standard’’  for
he  treatment  of  DME.18 Despite  this,  laser  offers  subop-
imal  results,  never  mind  the  possible  complications  due  to
he  burning  of  the  external  retina.In  2008,  Faghihi  et  al.36
emonstrated  that  a  single  dose  of  BVZ  or  BVZ  +  TCL  showed
uperiority  in  diminishing  CMT  with  patients  with  DME  in
omparison  to  the  laser  alone.  Regardless,  the  effect  of
VZ  on  monotherapy  was  short,  and  the  decrease  of  CMT
ith  an  improvement  of  BCVA  only  correlated  the  BVZ  +  TCL
roup.36 In  2010,  Solaiman  et  al.  compared  laser  and  BVZ
reatment  against  the  monotherapy  of  either  one,  and  his
esults  indicated  an  improvement  in  the  BCVA  and  CMT  in  the
roups  that  were  treated  with  BVZ  in  combination  with  laser
s  a  starting  therapy.48 In  2011,  DRCR.net  published  results
omparing  combined  therapy  using  macular  lasers  and  BVZ
r  TCL.  After  receiving  panphotocoagulation  laser  treat-
ent,  the  visual  improvement  was  greater  in  groups  that
eceived  BVZ  or  TCL,  although  there  were  no  differences
n  muscular  thickness,  suggesting  that  combined  therapies
tilizing  laser  +  BVZ  or  laser  +  TCL  were  superior  to  laser
onotherapy.51 The  same  year,  Wang  et  al.  demonstrated
he  beneﬁcial  effects  of  BVZ  as  a monotherapy  or  in  com-
ination  with  TCL  in  the  treatment  of  DMC,  without  there
eing  a  difference  between  the  two  groups.  In  2012,  Soheil-
an  et  al.52 published  results  comparing  BVZ  monotherapy,
VZ  +  TCL  and  macular  laser  monotherapy.  The  group  with
he  laser  did  not  obtain  a signiﬁcant  improvement  on  BCVA,
ut  although  the  BCVA  improvement  in  the  BVZ  group  was
igniﬁcant  during  the  ﬁrst  6  months,  there  was  no  signiﬁ-
ant  difference  between  the  BVZ  group  and  the  combined
reatment  group  (BVZ  +  TCL)  at  the  end  of  the  treatment.
lthough  the  CMT  reduction  was  greater  in  the  BVZ  group,
here  were  also  no  signiﬁcant  differences  between  the  3
roups.52 To  our  knowledge  upon  the  printing  of  this  publi-
ation,  the  only  study  to  utilize  a  BVZ  +  TCL  +  macular  laser
ombined  triple  therapy  was  published  by  Chan  et  al.  in
012,53 who  compared  the  triple  therapy  to  laser  monother-
py.  Regardless,  unlike  our  study,  TCL  administration  was
ubtenonian.  They  reported  an  important  decrease  and  sus-
ained  CMT  in  the  combined  therapy  group,  when  compared
o  laser  monotherapy.53
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Table  2  Results  by  groups.
Group  Standard  deviation  Average  Difference  Value  of  p
BVZ  +  SPMC Initial/Final  BCVA 0.1959  0.175  0.5658  .010
Initial/Final  CMT  173.60  137.08  50.1164  .019
Initial/Final  IOP  0.79  −0.08333  0.2289  .723
BVZ +  TCL  +  SPMC Initial/Final  BCVA  0.1603  0.07143  0.6061  .283
Initial/Final  CMT  133.87  94.71429  50.5996  .110
Initial/Final  IOP  3.3594  −2.42857  1.2697  .104
BVZ +  TCL Initial/Final  BCVA  0.1401  −0.01818  0.0422  .676
Initial/Final  CMT  61.63  32.63636  18.5836  .110
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The  majority  of  the  reports  which  include  combined  ther-
pies  in  DME  demonstrate  the  superiority  of  any  one  of  them
ver  laser  monotherapy,25,33,36,40,41,43,47--49,52,53 and  the  small
mpact  when  using  TCL.26,36,45--47,51--53 Our  results  indicate
hat  the  BVZ  +  laser  combined  therapy  during  the  ‘‘loading
hase’’  is  signiﬁcantly  superior  to  therapies  that  included
CL,  in  achieving  an  BCVA  improvement  and  a  CMT  decrease,
nd  we  suggest  that  this  combination  be  repeated  PRN  in
ong-term  follow-up.
One  possible  limitation,  owing  to  the  methodological
esign  of  our  study  (which  did  not  include  monotherapies)  is
hat  we  could  not  conclude,  as  previous  publications  have,
f  the  combination  of  anti-angiogenic  +  laser  is  equal  to  or
uperior  than  monotherapy  with  anti-angiogenics.  Regard-
ess,  this  was  not  the  object  of  our  study.  Another  of  the
imitations  of  our  study  is  that  we  only  evaluated  the  ther-
py  during  the  ‘‘loading  phase.’’  It  would  be  interesting  to
ollow-up  on  these  patients  in  the  long  term,  with  the  aim  of
etermining  if  this  therapeutic  combination  could  addition-
lly  be  effective  in  prolonging  the  intervals  of  the  retreats
n  the  long  term.
onclusion
ur  study  shows  that  out  of  the  combined  therapies  during
he  ‘‘loading  phase’’  in  DME  treatment,  the  combination  of
VZ  and  SMPC  was  the  best  option.  However,  further  studies
re  necessary,  with  a  longer  follow-up  period  and  a  larger
umber  of  participants,  to  establish  this  alternative  as  a  ﬁrst
reatment  option.
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